Wu Zubo, Shu Defeng, Wu Suyuan, Cai Pengcheng, Liang Tao
Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Neurosci. 2024 Mar 12;18:1374567. doi: 10.3389/fnins.2024.1374567. eCollection 2024.
To explore the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) and the risk of cognitive impairment in Parkinson's disease (PD-CI).
A case-control study involving 100 hospitalized PD patients and 60 healthy controls was carried out. Serum Lp-PLA2 level was detected by automatic biochemical analyzer. Based on whether Parkinson's patients have cognitive impairment, PD patients were subdivided to analyze the clinical value of Lp-PLA2. Relationship between Lp-PLA2 and PD-CI risk was analyzed by logistic regression. Diagnostic value of Lp-PLA2 in PD-CI patients was investigated using receiver's operator characteristic curves.
The levels of serum Lp-PLA2 activity in Parkinson's disease with normal cognition (PD-NC) and PD-CI patients were significantly higher than those in healthy controls (HCs), respectively. Furthermore, compared to the PD-NC group, the serum Lp-PLA2 activity level was significantly higher in PD-CI patients. Multivariable logistic regression analysis indicated that higher Lp-PLA2 level was an independent risk factor for PD patients with cognitive impairment. Moreover, the area under the efficacy curve of Lp-PLA2 for predicting PD-CI is 0.659.
Our study shows that higher levels of Lp-PLA2 activity in PD patients are associated with the risk of developing cognitive impairment. Therefore, given the wide availability, safety, and convenience of monitoring serum Lp-PLA2 activity, it may serve as an early biomarker for cognitive impairment in PD patients.
探讨脂蛋白相关磷脂酶A2（Lp-PLA2）与帕金森病认知障碍（PD-CI）风险之间的关联。
开展一项病例对照研究，纳入100例住院帕金森病患者和60例健康对照。采用自动生化分析仪检测血清Lp-PLA2水平。根据帕金森病患者是否存在认知障碍，对帕金森病患者进行细分，以分析Lp-PLA2的临床价值。通过逻辑回归分析Lp-PLA2与PD-CI风险之间的关系。使用受试者工作特征曲线研究Lp-PLA2在PD-CI患者中的诊断价值。
认知正常的帕金森病（PD-NC）患者和PD-CI患者的血清Lp-PLA2活性水平分别显著高于健康对照（HCs）。此外，与PD-NC组相比，PD-CI患者的血清Lp-PLA2活性水平显著更高。多变量逻辑回归分析表明，较高的Lp-PLA2水平是帕金森病认知障碍患者的独立危险因素。此外，Lp-PLA2预测PD-CI的效能曲线下面积为0.659。
我们的研究表明，帕金森病患者中较高水平的Lp-PLA2活性与发生认知障碍的风险相关。因此，鉴于监测血清Lp-PLA2活性具有广泛的可及性、安全性和便利性，它可能作为帕金森病患者认知障碍的早期生物标志物。
